Discontinued — last reported Q3 '25
Operating Expenses
Impairment Charges
This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2022
Last reportedQ3 2025
How to read this metric
An increase signals poor past investment decisions or deteriorating market conditions, which is generally viewed negatively by investors.
Detailed definition
These are non-cash charges recognized when the carrying value of an asset exceeds its fair market value. Such charges in...
Peer comparison
Common in large, diversified firms that frequently acquire or divest business units.
Metric ID:
impairment_chargesHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $153.96M | $153.96M | $153.96M | $153.96M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $69.44M |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | — | — | — | — | — |
| YoY Change | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | — | — |
Range$0.00 – $153.96M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Impairment Charges at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's impairment charges?
- Royalty Pharma (RPRX) reported impairment charges of $69.44M in Q1 2026.
- What does impairment charges mean?
- A write-down of the value of assets that are no longer worth what they are listed for.